Research on the Configurational Paths of International Competitiveness of Chinese RPG Games
Information and Knowledge Management · 2026 · 7 (1)
DOI: 10.23977/infkm.2026.070104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Information and Knowledge Management, 2026.
Abstract (Originalsprache)
: Chinese role-playing game (RPG) exports are plagued by cultural discount and resource misallocation. Existing research struggles to explain the causal complexity underlying the formation of their international competitiveness. Grounded in cultural discount theory and the resource-based view, this study constructs a framework of culture-centric core with factor combination adaptation and adopts the fuzzy-set qualitative comparative analysis (fsQCA) method to analyze 154 overseas player datasets. The findings reveal that cultural-gameplay integration is a quasi-necessary condition for high competitiveness, while technological factors only play a supporting role. Three equivalent high-competitiveness paths are identified: culture + narrative integration, culture + IP linkage, and culture + localization adaptation. Two failure modes are also detected: lack of culture + technological misallocation and lack of culture + IP redundancy. This study uncovers the configurational mechanism of multi-factor synergetic adaptation and provides differentiated overseas expansion pathways for developers with varying resource endowments.
Zitieren
APA
(2026). Research on the Configurational Paths of International Competitiveness of Chinese RPG Games. Information and Knowledge Management, 7(1). https://doi.org/10.23977/infkm.2026.070104
Vancouver
Research on the Configurational Paths of International Competitiveness of Chinese RPG Games. Information and Knowledge Management. 2026;7(1). doi:10.23977/infkm.2026.070104
BibTeX
@article{euvimed2026,
title = {Research on the Configurational Paths of International Competitiveness of Chinese RPG Games},
journal = {Information and Knowledge Management},
year = {2026},
volume = {7},
number = {1},
doi = {10.23977/infkm.2026.070104}
}
EUVIMED